WallStreetZenWallStreetZen

NASDAQ: CERE
Cerevel Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CERE

Based on 7 analysts offering 12 month price targets for Cerevel Therapeutics Holdings Inc.
Min Forecast
$45.00+10.73%
Avg Forecast
$45.00+10.73%
Max Forecast
$45.00+10.73%

Should I buy or sell CERE stock?

Based on 7 analysts offering ratings for Cerevel Therapeutics Holdings Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
7 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CERE stock forecasts and price targets.

CERE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-16
lockedlocked$00.00+00.00%2023-12-28
lockedlocked$00.00+00.00%2023-12-22
lockedlocked$00.00+00.00%2023-12-08
lockedlocked$00.00+00.00%2023-12-07
Piper Sandler
Top 23%
78
HoldDowngrades$45.00+10.73%2023-12-07
Cantor Fitzgerald
Top 6%
95
HoldDowngrades$45.00+10.73%2023-12-07

1 of 1

Forecast return on equity

Is CERE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.99%

Forecast return on assets

Is CERE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CERE revenue forecast

What is CERE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$13.5M
Avg 2 year Forecast
$19.5M
Avg 3 year Forecast
$94.2M

CERE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CERE$40.64$45.00+10.73%Hold
PCVX$70.21$96.00+36.73%Strong Buy
SMMT$10.92$7.50-31.32%Strong Buy
ROIV$10.39$17.57+69.11%Strong Buy
LEGN$43.33$78.38+80.88%Strong Buy
View Top Biotech Stocks

Cerevel Therapeutics Holdings Stock Forecast FAQ

Is Cerevel Therapeutics Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: CERE) stock is to Hold CERE stock.

Out of 7 analysts, 0 (0%) are recommending CERE as a Strong Buy, 0 (0%) are recommending CERE as a Buy, 7 (100%) are recommending CERE as a Hold, 0 (0%) are recommending CERE as a Sell, and 0 (0%) are recommending CERE as a Strong Sell.

If you're new to stock investing, here's how to buy Cerevel Therapeutics Holdings stock.

What is CERE's revenue growth forecast for 2025-2027?

(NASDAQ: CERE) Cerevel Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.69%.

Cerevel Therapeutics Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CERE's revenue for 2025 to be $2,463,272,641, with the lowest CERE revenue forecast at $2,463,272,641, and the highest CERE revenue forecast at $2,463,272,641. On average, 1 Wall Street analysts forecast CERE's revenue for 2026 to be $3,552,797,079, with the lowest CERE revenue forecast at $3,552,797,079, and the highest CERE revenue forecast at $3,552,797,079.

In 2027, CERE is forecast to generate $17,162,742,812 in revenue, with the lowest revenue forecast at $17,162,742,812 and the highest revenue forecast at $17,162,742,812.

What is CERE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CERE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CERE's Price Target?

According to 7 Wall Street analysts that have issued a 1 year CERE price target, the average CERE price target is $45.00, with the highest CERE stock price forecast at $45.00 and the lowest CERE stock price forecast at $45.00.

On average, Wall Street analysts predict that Cerevel Therapeutics Holdings's share price could reach $45.00 by Feb 16, 2025. The average Cerevel Therapeutics Holdings stock price prediction forecasts a potential upside of 10.73% from the current CERE share price of $40.64.

What is CERE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CERE) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.